Rallybio Corporaton (RLYB)

$9.09 -0.27 (-2.88%)
Market Cap 49.51M
Revenue (ttm) 640,000.00
Net Income (ttm) -57.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -9,028.13%
Debt to Equity Ratio 0.00
Volume 140,300
Avg Vol 149,242
Day's Range N/A - N/A
Shares Out 5.29M
Stochastic %K 9%
Beta -1.13
Analysts Hold
Price Target $8.00

Company Profile

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-tar...

Industry: Biotechnology
Sector: Healthcare
Phone: 203 859 3820
Address:
234 Church Street, Suite 1020, New Haven, United States
aletz
aletz Mar. 12 at 1:48 PM
$RLYB https://www.biostockinfo.com/t-cell-engagers-tce-the-race-to-reset-the-immune-system-and-the-biotechs-positioning-to-win/ This explains TCE, and how CDRX (Candid) will try to shape the space after RLYB merger
0 · Reply
skyrockets_Inc
skyrockets_Inc Mar. 10 at 6:03 PM
$NEUP I expect news to happen in next 2-3 weeks MAX (by end of Q1). All the strategic alternative plays lately have been bangers...expect this to be nothing less. Still has a -30% downside risk if RM deal is TERRIBLE but given they have over 12 competing offers and already rejected a 4.75/share buyout, a bad deal is less likely IMO. $VYNE, $RLYB, $SNSE, all ended amazingly as predicted. This one should be NEXT! LFG!
0 · Reply
skyrockets_Inc
skyrockets_Inc Mar. 5 at 7:56 PM
$RLYB Response from IR on my question regarding selling the RLYB116 asset BEFORE the merger closing: Q: "Is RallyBio actively trying to sell the asset? And if so will a cash dividend be paid to existing investors prior to the merger? " A: "You are correct that Candid will not be progressing the existing RLYB assets. We will certainly be exploring opportunities to partner the assets in the coming months prior to the deal with Candid closing. Some of the current Rallybio team members do have an interest in the assets. Our objective will be to get as much value ascribed to the CVRs as possible. ""
0 · Reply
Stackdoe101
Stackdoe101 Mar. 5 at 2:12 PM
$RLYB 🙃✨
0 · Reply
skyrockets_Inc
skyrockets_Inc Mar. 3 at 7:20 PM
$NEUP Here are my predicted likely outcomes for the strategic process (in order of likelihood imo): 1). Reverse merger w/ either asset sales or CVRs , or combination of both. This would mimic a similar deal to what $RLYB just did. However, $RLYB had a better cash position so the price movement in this option will depend entirely on how good the terms of the RM are. --> -30% downside risk for a potential 2-3x upside. 2). Buyout. Lynx1 group offered 4.75 for the entire company so there is precedent for it. The BOD rejected this offer because ... "Simply stated, Lynx1’s non-binding proposal does not present an attractive value, and certainly not one that would compel the Board to consider abandoning its ongoing strategic review process – especially given that the Company has already received a substantial number of competing indications of interest, with nearly a dozen that have already advanced to NDAs and separate process letter proposals. " --> 2x minimum, 3-4x possible
0 · Reply
prismmarketview
prismmarketview Mar. 3 at 3:17 PM
Rallybio Corp. (NASDAQ: $RLYB) is set to merge into privately held Candid Therapeutics in an all‑stock reverse merger backed by a $505.5 million private financing, creating a Nasdaq‑listed Candid with roughly $700 million in cash, Candid holders owning about 57.6% of the combined company, new PIPE investors about 38.8%, and legacy Rallybio shareholders just 3.6%, plus CVRs tied to any monetization of Rallybio’s legacy assets, while advancing lead T‑cell engager cizutamig toward Phase 2 trials in autoimmune disease. https://prismmarketview.com/rallybio-to-merge-with-candid-therapeutics-in-500m-backed-reverse-merger/
0 · Reply
BioShark
BioShark Mar. 3 at 6:14 AM
$RLYB three months later… boom boom
0 · Reply
skyrockets_Inc
skyrockets_Inc Mar. 3 at 12:33 AM
$RLYB sold half my shares today. holding the remaining half in case RLYB116 asset sale/cash dividend happens in the near-term. Not expecting it, would be an additional happy surprise. Otherwise, I'll hold remaining half for CVRs. Congrats to all LONGS here :)
1 · Reply
topstockalerts
topstockalerts Mar. 2 at 9:57 PM
Top Gainers PT2 $RLYB $RCON $SABR $AERT $RCAX
0 · Reply
SDBiotechInvestor
SDBiotechInvestor Mar. 2 at 8:45 PM
$NEUP - Went long today after being in $RLYB for several months. Think we will see a similar outcome as Sky mentions below. Lots of ways to win here.
0 · Reply
Latest News on RLYB
Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript

Mar 2, 2026, 4:17 PM EST - 17 days ago

Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript

Tiny Biotech Rallybio Stock Surges As $500 Million-Backed Merger Fuels Investor Optimism

Mar 2, 2026, 10:51 AM EST - 17 days ago

Tiny Biotech Rallybio Stock Surges As $500 Million-Backed Merger Fuels Investor Optimism

Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

Mar 2, 2026, 8:00 AM EST - 17 days ago

Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

Rallybio Shares Successful Early-Stage Results for Rare Disease Drug; New Trial Set for Late 2026

Feb 17, 2026, 10:46 AM EST - 4 weeks ago

Rallybio Shares Successful Early-Stage Results for Rare Disease Drug; New Trial Set for Late 2026

Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement

Feb 17, 2026, 8:00 AM EST - 4 weeks ago

Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement

Rallybio Announces Reverse Stock Split of Common Stock

Feb 3, 2026, 4:05 PM EST - 6 weeks ago

Rallybio Announces Reverse Stock Split of Common Stock

Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 6, 2025, 8:00 AM EST - 4 months ago

Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates

Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

Sep 25, 2025, 8:00 AM EDT - 6 months ago

Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program

Sep 3, 2025, 8:00 AM EDT - 7 months ago

Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program

Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 7, 2025, 8:00 AM EDT - 8 months ago

Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Why Is Microcap Rallybio Stock Trading Higher On Tuesday?

Jul 8, 2025, 9:44 AM EDT - 9 months ago

Why Is Microcap Rallybio Stock Trading Higher On Tuesday?

Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals

Jul 8, 2025, 8:00 AM EDT - 9 months ago

Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals

Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

Jun 12, 2025, 8:00 AM EDT - 10 months ago

Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates

May 8, 2025, 8:00 AM EDT - 11 months ago

Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates

Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference

Apr 29, 2025, 8:00 AM EDT - 11 months ago

Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference

Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints

Apr 8, 2025, 1:01 PM EDT - 1 year ago

Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints

Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT

Apr 8, 2025, 8:00 AM EDT - 1 year ago

Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT

Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 13, 2025, 8:00 AM EDT - 1 year ago

Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Rallybio to Present at the TD Cowen 45th Annual Health Care Conference

Feb 25, 2025, 8:00 AM EST - 1 year ago

Rallybio to Present at the TD Cowen 45th Annual Health Care Conference

Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial

Feb 11, 2025, 8:00 AM EST - 1 year ago

Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial

Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025

Jan 10, 2025, 8:00 AM EST - 1 year ago

Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025

Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting

Dec 10, 2024, 8:00 AM EST - 1 year ago

Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting

Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025

Dec 2, 2024, 8:00 AM EST - 1 year ago

Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025

Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women

Nov 27, 2024, 8:00 AM EST - 1 year ago

Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women

Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference

Nov 26, 2024, 8:00 AM EST - 1 year ago

Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference

Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor

Nov 25, 2024, 8:00 AM EST - 1 year ago

Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor

Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212

Nov 21, 2024, 8:00 AM EST - 1 year ago

Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212

Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 7, 2024, 8:00 AM EST - 1 year ago

Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates

Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT

Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting

Sep 30, 2024, 8:00 AM EDT - 1 year ago

Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting

Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting

Sep 23, 2024, 8:00 AM EDT - 1 year ago

Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting

Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit

Sep 10, 2024, 8:00 AM EDT - 1 year ago

Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit

Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree

Sep 9, 2024, 5:15 PM EDT - 1 year ago

Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree

Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis

Aug 29, 2024, 8:00 AM EDT - 1 year ago

Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis

National Vision Releases 2023 Sustainability Report

Aug 27, 2024, 8:00 AM EDT - 1 year ago

National Vision Releases 2023 Sustainability Report

ACNT

Rallybio to Present at Upcoming Investor Conferences

Aug 27, 2024, 8:00 AM EDT - 1 year ago

Rallybio to Present at Upcoming Investor Conferences

Rallybio Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Rallybio Reports Second Quarter 2024 Financial Results and Provides Business Updates

Rallybio to Present at the 2024 Jones Healthcare Seaside Summit

Jul 9, 2024, 8:00 AM EDT - 1 year ago

Rallybio to Present at the 2024 Jones Healthcare Seaside Summit

Rallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations

Jun 17, 2024, 8:00 AM EDT - 1 year ago

Rallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations

Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates

May 9, 2024, 8:00 AM EDT - 2 years ago

Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates

Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference

May 7, 2024, 8:00 AM EDT - 2 years ago

Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference

FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting

Apr 17, 2024, 4:01 PM EDT - 2 years ago

FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting

Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Apr 10, 2024, 4:01 PM EDT - 2 years ago

Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting

Apr 1, 2024, 10:05 AM EDT - 2 years ago

Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting

Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results

Rallybio to Present at the TD Cowen 44th Annual Health Care Conference

Feb 26, 2024, 8:00 AM EST - 2 years ago

Rallybio to Present at the TD Cowen 44th Annual Health Care Conference

Rallybio Announces Portfolio Prioritization and Provides Corporate Update

Feb 6, 2024, 8:00 AM EST - 2 years ago

Rallybio Announces Portfolio Prioritization and Provides Corporate Update

Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024

Jan 4, 2024, 8:00 AM EST - 2 years ago

Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024

aletz
aletz Mar. 12 at 1:48 PM
$RLYB https://www.biostockinfo.com/t-cell-engagers-tce-the-race-to-reset-the-immune-system-and-the-biotechs-positioning-to-win/ This explains TCE, and how CDRX (Candid) will try to shape the space after RLYB merger
0 · Reply
skyrockets_Inc
skyrockets_Inc Mar. 10 at 6:03 PM
$NEUP I expect news to happen in next 2-3 weeks MAX (by end of Q1). All the strategic alternative plays lately have been bangers...expect this to be nothing less. Still has a -30% downside risk if RM deal is TERRIBLE but given they have over 12 competing offers and already rejected a 4.75/share buyout, a bad deal is less likely IMO. $VYNE, $RLYB, $SNSE, all ended amazingly as predicted. This one should be NEXT! LFG!
0 · Reply
skyrockets_Inc
skyrockets_Inc Mar. 5 at 7:56 PM
$RLYB Response from IR on my question regarding selling the RLYB116 asset BEFORE the merger closing: Q: "Is RallyBio actively trying to sell the asset? And if so will a cash dividend be paid to existing investors prior to the merger? " A: "You are correct that Candid will not be progressing the existing RLYB assets. We will certainly be exploring opportunities to partner the assets in the coming months prior to the deal with Candid closing. Some of the current Rallybio team members do have an interest in the assets. Our objective will be to get as much value ascribed to the CVRs as possible. ""
0 · Reply
Stackdoe101
Stackdoe101 Mar. 5 at 2:12 PM
$RLYB 🙃✨
0 · Reply
skyrockets_Inc
skyrockets_Inc Mar. 3 at 7:20 PM
$NEUP Here are my predicted likely outcomes for the strategic process (in order of likelihood imo): 1). Reverse merger w/ either asset sales or CVRs , or combination of both. This would mimic a similar deal to what $RLYB just did. However, $RLYB had a better cash position so the price movement in this option will depend entirely on how good the terms of the RM are. --> -30% downside risk for a potential 2-3x upside. 2). Buyout. Lynx1 group offered 4.75 for the entire company so there is precedent for it. The BOD rejected this offer because ... "Simply stated, Lynx1’s non-binding proposal does not present an attractive value, and certainly not one that would compel the Board to consider abandoning its ongoing strategic review process – especially given that the Company has already received a substantial number of competing indications of interest, with nearly a dozen that have already advanced to NDAs and separate process letter proposals. " --> 2x minimum, 3-4x possible
0 · Reply
prismmarketview
prismmarketview Mar. 3 at 3:17 PM
Rallybio Corp. (NASDAQ: $RLYB) is set to merge into privately held Candid Therapeutics in an all‑stock reverse merger backed by a $505.5 million private financing, creating a Nasdaq‑listed Candid with roughly $700 million in cash, Candid holders owning about 57.6% of the combined company, new PIPE investors about 38.8%, and legacy Rallybio shareholders just 3.6%, plus CVRs tied to any monetization of Rallybio’s legacy assets, while advancing lead T‑cell engager cizutamig toward Phase 2 trials in autoimmune disease. https://prismmarketview.com/rallybio-to-merge-with-candid-therapeutics-in-500m-backed-reverse-merger/
0 · Reply
BioShark
BioShark Mar. 3 at 6:14 AM
$RLYB three months later… boom boom
0 · Reply
skyrockets_Inc
skyrockets_Inc Mar. 3 at 12:33 AM
$RLYB sold half my shares today. holding the remaining half in case RLYB116 asset sale/cash dividend happens in the near-term. Not expecting it, would be an additional happy surprise. Otherwise, I'll hold remaining half for CVRs. Congrats to all LONGS here :)
1 · Reply
topstockalerts
topstockalerts Mar. 2 at 9:57 PM
Top Gainers PT2 $RLYB $RCON $SABR $AERT $RCAX
0 · Reply
SDBiotechInvestor
SDBiotechInvestor Mar. 2 at 8:45 PM
$NEUP - Went long today after being in $RLYB for several months. Think we will see a similar outcome as Sky mentions below. Lots of ways to win here.
0 · Reply
topstockalerts
topstockalerts Mar. 2 at 8:45 PM
$RLYB setting up nicely.. 🍾
0 · Reply
VortexityTrades
VortexityTrades Mar. 2 at 8:30 PM
)No doubt, @SqueezeSharkie straight up owned this year so far!! If you haven't yet, smash that FOLLOW button it's literally just one click and it doesn’t cost you anything. $MVO $RLYB $AURE $RCAX > on watch as well
0 · Reply
topstockalerts
topstockalerts Mar. 2 at 8:16 PM
$RLYB Quiet base forming after prolonged pressure. Volatility compressing which usually precedes expansion. Watching for strong close through range highs.
0 · Reply
topstockalerts
topstockalerts Mar. 2 at 7:59 PM
Top Gainers $STAK $TURB $CD $RCAX $RLYB
0 · Reply
Skinner12345
Skinner12345 Mar. 2 at 7:05 PM
$RLYB 🚀
0 · Reply
VortexityTrades
VortexityTrades Mar. 2 at 6:53 PM
<@SqueezeSharkie is operating on a whole different level, easily ahead of 90% of the traders on this platform. If you’re not paying attention yet, you’re missing out. Go give him a follow it’s completely free and only takes a second 💎 $UPXI $RLYB $RCON $JFB >> on close watch
0 · Reply
Peak_Big
Peak_Big Mar. 2 at 5:44 PM
$RLYB
0 · Reply
topstockalerts
topstockalerts Mar. 2 at 4:38 PM
Top Gainers PT2 $ONDG $RLYB $DFNS $AERT $CRCG
0 · Reply
skyrockets_Inc
skyrockets_Inc Mar. 2 at 4:36 PM
$NEUP Now that $RLYB has exploded I've added to my position here. Still think an outcome on this by end of Q1 (March 31). Strat alts since Nov and had hostile takeover attempt for 4.75/share which got rejected. Several valuable assets still in pipeline with one partnered w/ MERCK. Likely going to be RM here as only 1 employee left. RM w/ CVRS similar to $RLYB likely today. Cash value not as good as RallyBio so downside risk is more, I'd say -30% downside risk for a potential 2-3x upside. LFG!
1 · Reply
Swedish_Chef
Swedish_Chef Mar. 2 at 4:32 PM
$RLYB buffering… just needs some volume
0 · Reply
topstockalerts
topstockalerts Mar. 2 at 3:42 PM
$RLYB Buyers stepping in with conviction. Price responds quickly to demand. That’s what strong trends look like 💪.
0 · Reply